CompanyOverview|NYSE:NVO] Despite a massively successful run as Chief Executive Officer (CEO) of pharma giant Novo Nordisk ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

The European Medicines Agency's safety committee has concluded that a potentially dangerous eye condition is a very rare side ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

Ozempic helped Novo Nordisk gain an early lead in the weight loss industry, but competition is nipping at the company's heels ...

In the late 2010s, Novo Nordisk shelved a weekly obesity treatment that targeted three hormones at once, though it caused ...

The European Medicines Agency's (EMA) safety committee (PRAC) has concluded its review of medicines containing semaglutide ...

Women employed at Novo Nordisk A/S are now paid more on average than the men working at the maker of blockbuster drugs Wegovy ...

A long-acting medicine developed by Novo Nordisk has been recommended as a treatment option for young people with growth ...

Novo Nordisk's (NVO) weight loss drug semaglutide (Ozempic, Wegovy, Rybelsus) is linked to a rare eye condition called NAION ...